Leap Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 54
- Market Cap
- $113.2M
- Website
- http://www.leaptx.com
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01239134
- Locations
- 🇺🇸
Immunotherapeutics Core / Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2024. All Rights Reserved by MedPath